A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients

Abstract Acute leukemias (AL) comprise a heterogeneous group of hematologic malignancies, and individual patient responses to treatment can be difficult to predict. Monitoring of minimal residual disease (MRD) is thus very important and holds great potential for improving treatment strategies. Commo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2013-10, Vol.37 (10), p.1363-1373
Hauptverfasser:	Jancuskova, Tereza, Plachy, Radek, Stika, Jiri, Zemankova, Lucie, Hardekopf, David W, Liehr, Thomas, Kosyakova, Nadezda, Cmejla, Radek, Zejskova, Lenka, Kozak, Tomas, Zak, Pavel, Zavrelova, Alzbeta, Havlikova, Pavlina, Karas, Michal, Junge, Annelore, Ramel, Christian, Pekova, Sona
Format:	Artikel
Sprache:	eng
Schlagworte:	Abnormal Karyotype Acute leukemia Base Sequence Biomarkers, Tumor - genetics Cell Line, Tumor Chromosome Aberrations Chromosome Banding Chromosome Breakpoints Chromosome Mapping Chromosome microdissection Cytogenetics DNA-Binding Proteins - genetics Hematology, Oncology and Palliative Medicine Histone-Lysine N-Methyltransferase Humans K562 Cells Leukemia - diagnosis Leukemia - genetics Minimal residual disease Myeloid-Lymphoid Leukemia Protein - genetics Neoplasm, Residual - diagnosis Neoplasm, Residual - genetics Next-generation sequencing Nuclear Proteins - genetics Oncogene Proteins, Fusion - genetics Personalized medicine Transcriptional Elongation Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!